Diagnosis and the debatable issues of the treatment of heart failure with preserved ejection fraction

Heart failure with preserved fraction (HFpEF) amount for a half of the general heart failure and increasing progressively. In this review we discuss the issues of pathogenesis of HFpEF, illuminated in the recent literature in the last years. Considering the heterogeneity of the pathophysiology of this syndrome and the results of large-scale studies conducted nowadays, it considers the debatable treatment issues of the applying different drugs in the prevention of HFpEF.

• Publication year

  2018

• Venue

  CardioSomatics

• Publication date

  2018-12-15

• Fields of study

  Medicine

• Identifiers
  DOI 10.26442/22217185.2018.4.000013
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• An integrative translational approach to study heart failure with preserved ejection fraction: a position paper from the Working Group on Myocardial Function of the European Society of Cardiology

  2018cited by this paper
• Hospitalisation in Patients With Heart Failure With Preserved Ejection Fraction

  2018cited by this paper
• Comparison of lercanidipine plus hydrochlorothiazide vs. lercanidipine plus enalapril on micro and macrocirculation in patients with mild essential hypertension

  2017cited by this paper
• A Clinical Perspective of Anti-Fibrotic Therapies for Cardiovascular Disease

  2017cited by this paper
• Current Understanding of the Pathophysiology of Myocardial Fibrosis and Its Quantitative Assessment in Heart Failure

  2017cited by this paper
• Drug treatment effects on outcomes in heart failure with preserved ejection fraction: a systematic review and meta-analysis

  2017cited by this paper
• Metformin in heart failure patients

  2017cited by this paper
• Prognostic Implications of Changes in N-Terminal Pro-B-Type Natriuretic Peptide in Patients With Heart Failure.

  2016cited by this paper
• Coronary vascular regulation, remodelling, and collateralization: mechanisms and clinical implications on behalf of the working group on coronary pathophysiology and microcirculation.

  2015cited by this paper
• Remodelling the extracellular matrix in development and disease

  2014cited by this paper
• Fibrosis and cardiac function in obesity: a randomised controlled trial of aldosterone blockade

  2013influential reference
• A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation.

  2013influential reference
• Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial.

  2013cited by this paper
• Pulmonary Hypertension in Heart Failure With Preserved Ejection Fraction: A Target of Phosphodiesterase-5 Inhibition in a 1-Year Study

  2012cited by this paper
• The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial.

  2012cited by this paper
• Heart failure with preserved ejection fraction in the elderly: scope of the problem

  2012influential reference
• Targeting fibrosis for the treatment of heart failure: a role for transforming growth factor-β.

  2012cited by this paper
• Rapid, Direct Effects of Statin Treatment on Arterial Redox State and Nitric Oxide Bioavailability in Human Atherosclerosis via Tetrahydrobiopterin-Mediated Endothelial Nitric Oxide Synthase Coupling

  2011cited by this paper
• Determinants of exercise intolerance in elderly heart failure patients with preserved ejection fraction.

  2011cited by this paper
• Results of the Randomized Aldosterone Antagonism in Heart Failure with Preserved Ejection Fraction trial (RAAM-PEF).

  2011cited by this paper
• Effect of Metformin on mortality in patients with heart failure and type 2 diabetes mellitus.

  2010cited by this paper
• Amlodipine improves endothelial function and metabolic parameters in patients with hypertension.

  2009cited by this paper
• Evaluation and optimization of antifibrotic activity of cinnamoyl anthranilates.

  2009cited by this paper
• Natural history of markers of collagen turnover in patients with early diastolic dysfunction and impact of eplerenone.

  2009cited by this paper
• The Hong Kong diastolic heart failure study: a randomised controlled trial of diuretics, irbesartan and ramipril on quality of life, exercise capacity, left ventricular global and regional function in heart failure with a normal ejection fraction

  2008cited by this paper
• Prognosis of heart failure with preserved ejection fraction: a 5 year prospective population-based study.

  2008cited by this paper
• How to explain the differences between renin angiotensin system modulators.

  2005cited by this paper
• Role of endothelin in fibrosis and anti‐fibrotic potential of bosentan

  2005cited by this paper
• Losartan-Dependent Regression of Myocardial Fibrosis Is Associated With Reduction of Left Ventricular Chamber Stiffness in Hypertensive Patients

  2002cited by this paper
• Growth inhibitory activity of indapamide on vascular smooth muscle cells.

  2001cited by this paper
• Lisinopril-Mediated Regression of Myocardial Fibrosis in Patients With Hypertensive Heart Disease

  2000cited by this paper
• Arterial compliance and baroreceptor sensitivity after chronic treatment with indapamide.

  1988cited by this paper

• Interleukin 6 Signalling in Heart Failure With Preserved and Reduced Ejection Fraction.

  2024cites this paper
• Effect of combination antihypertensive therapy, including renin-angiotensin-aldosterone system inhibitors, on oxidative stress and arterial remodeling in hypertensive patients with heart failure with preserved ejection fraction

  2021cites this paper
• Dynamics of Vascular Stiffness and Endothelial Function in Combination Therapy of Heart Failure with Preserved Ejection Fraction

  2020cites this paper